<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>ASAP Discovery Outputs on ASAP Discovery Consortium</title><link>https://asapdiscovery.org/outputs/</link><description>Recent content in ASAP Discovery Outputs on ASAP Discovery Consortium</description><generator>Hugo -- gohugo.io</generator><language>en-us</language><atom:link href="https://asapdiscovery.org/outputs/index.xml" rel="self" type="application/rss+xml"/><item><title>Viral Families</title><link>https://asapdiscovery.org/outputs/viral-families/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/viral-families/</guid><description>coronaviridae Coronavirus antiviral discovery is funded by NIAID grant U19AI171399 from the National Institutes of Health.
flaviviridae Flavivirus antiviral discovery is funded by NIAID grant U19AI171399 from the National Institutes of Health.
picornaviridae Picornavirus antiviral discovery is funded by NIAID grant U19AI171399 from the National Institutes of Health.
influenza ASAP is not currently funded to pursue antiviral discovery for pandemic influenza, but is very interested in exploring opportunities for funding discovery programs in this area.</description></item><item><title>Targeting Opportunities</title><link>https://asapdiscovery.org/outputs/targeting-opportunities/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/targeting-opportunities/</guid><description>SARS-CoV-2 / MERS-CoV Mpro protease Targeting Opportunity for SARS-CoV-2 / MERS-CoV Mpro protease [2023-03-19] Initial draft
Dengue NS2B-NS3 protease Targeting Opportunity for Dengue NS2B-NS3 protease [2023-03-22] Initial draft
Dengue NS2B-NS3 protease-helicase Targeting Opportunity for Dengue NS2B-NS3 protease-helicase [2023-03-21] Initial draft
Dengue NS5 RdRp Targeting Opportunity for Dengue NS5 RdRp [2023-03-27] Initial draft
Dengue NS5 RdRp Targeting Opportunity for Dengue NS5 RdRp [2023-03-27] Initial draft
Enterovirus A71 2A protease Targeting Opportunity for Enterovirus A71 2A protease [2023-03-22] Initial draft</description></item><item><title>Molecules</title><link>https://asapdiscovery.org/outputs/molecules/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/molecules/</guid><description>SARS-CoV-2 ns3 Mac1 macrodomain Program 2</description></item><item><title>Structures</title><link>https://asapdiscovery.org/outputs/structures/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/structures/</guid><description>Program 1 Program 2</description></item><item><title>Publications</title><link>https://asapdiscovery.org/outputs/publications/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/publications/</guid><description/></item><item><title>Mutation Data</title><link>https://asapdiscovery.org/outputs/mutation-data/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/mutation-data/</guid><description> Coronavirus MERS-CoV/SARS-CoV-2 Mpro Coronavirus nsp3-mac1 Item 3</description></item><item><title>Target Product Profiles (TPPs)</title><link>https://asapdiscovery.org/outputs/target-product-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-product-profiles/</guid><description/></item><item><title>Target Enabling Packages (TEPs)</title><link>https://asapdiscovery.org/outputs/target-enabling-packages/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-enabling-packages/</guid><description>SARS-CoV-2 / MERS-CoV Mpro Gene: 43740578 &amp;nbsp; Uniprot: P0C6U8 &amp;nbsp; EC: 3.4.22.69 Contributors: Alice Douangamath Daren Fearon Paul Gehrtz Petra Lukacik C. David Owen Efrat Resnick Claire Strain-Damerell Anthony Aimon Péter Ábrányi-Balogh José Brandão-Neto Anna Carbery Gemma Davison Alexandre Dias Thomas D. Downes Louise Dunnett James D. Firth S. Paul Jones Aaron Keeley György M. Keserü Hanna F. Klein Mathew P. Martin Martin E. M. Noble Peter O’Brien Ailsa Powell Rambabu N.</description></item><item><title>Assay Cascades</title><link>https://asapdiscovery.org/outputs/assay-cascade/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/assay-cascade/</guid><description>Coronavirus MERS-CoV/SARS-CoV-2 Mpro Coronavirus nsp3-mac1 Item 3</description></item><item><title>Assay Protocols</title><link>https://asapdiscovery.org/outputs/assay-protocols/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/assay-protocols/</guid><description>MERS-CoV Main Protease (Mpro) Fluorescence Dose Response This is a functional, biochemical assay used to identify treatments for viral infectious disease in MERS 3C-like main viral protease. Utilizing a direct enzyme activity measurement method, the experiment was performed in a 384-well plate reading the fluorescence intensity. This assay tested the mode of action of inhibition.
protocols.io
SARS-CoV-2 Main Protease (Mpro) Fluorescence Dose Response This is a functional, biochemical assay used to identify treatments for viral infectious disease that target SARS-CoV-2 3C-like main viral protease (MPro).</description></item><item><title>Target Candidate Profiles (TCPs)</title><link>https://asapdiscovery.org/outputs/target-candidate-profiles/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/target-candidate-profiles/</guid><description/></item><item><title>Hit-to-Lead</title><link>https://asapdiscovery.org/outputs/hit-to-lead/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/hit-to-lead/</guid><description>Program 1 Program 2</description></item><item><title>Hit-to-Lead</title><link>https://asapdiscovery.org/outputs/covalent-targeting/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/covalent-targeting/</guid><description>Program 1 Program 2</description></item><item><title>Lead Optimization</title><link>https://asapdiscovery.org/outputs/lead-optimization/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/lead-optimization/</guid><description>Program 1 Program 2</description></item><item><title>Preclinical program</title><link>https://asapdiscovery.org/outputs/preclinical/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/preclinical/</guid><description>SARS-CoV-2 Mpro</description></item><item><title>Investigational New Drug (IND) filings</title><link>https://asapdiscovery.org/outputs/investigational-new-drugs/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/investigational-new-drugs/</guid><description>Program 1 Program 2</description></item><item><title>Clinical trials</title><link>https://asapdiscovery.org/outputs/clinical-trials/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/clinical-trials/</guid><description>ASAP does not currently have any programs that have reached clinical trials.</description></item><item><title>New Drug Approvals</title><link>https://asapdiscovery.org/outputs/new-drug-approvals/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/new-drug-approvals/</guid><description>ASAP does not currently have any programs that have reached New Drug Approval (NDA) status.</description></item><item><title/><link>https://asapdiscovery.org/outputs/img/icons/readme/</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://asapdiscovery.org/outputs/img/icons/readme/</guid><description>Icons from The Noun Project Icons are CC-BY from The Noun Project
Credits (for CC-BY acknowledgments) assay-cascade.png : noun-chemistry-2954755 : Chemistry by Icon Factory from Noun Project clinical-trails.png : noun-medical-1053629 : medical by Raymond from Noun Project data.png : noun-save-5021426 : Save by Cetha Studio from Noun Project disease.png : noun-medical-3923610 : medical by Royyan Wijaya from Noun Project DMS.png : noun-mutation-4374976 : mutation by Adrien Coquet from Noun Project hit-to-lead.</description></item></channel></rss>